DNA甲基化表观签名作为Diamond-Blackfan贫血综合征的新型诊断工具
研究在80例携带不同核糖体蛋白基因致病变异的Diamond-Blackfan贫血综合征(DBAS)患者中,识别出高准确度的DNA甲基化表观签名,可区分范可尼贫血及其他表观签名阳性疾病,并开发出区分DBA6与DBA7亚型的分类器;在6例分子未明确病例中3例呈DBAS模式,其中2例经基因组测序找到致病变异。
要点
- 80例DBAS患者中识别出可区分范可尼贫血及其他表观签名阳性疾病的DNA甲基化表观签名。
- 开发出区分临床相似的DBA6与DBA7亚型的特异性DNA甲基化分类器。
- 6例分子未明确病例中3例呈DBAS模式,2例经基因组测序找到致病变异。
核心结论
- 作者提出DNA甲基化谱可作为DBAS的稳健诊断工具,为所有临床疑似患者提供生物标志物,并有助于解决意义未明变异和分子未明确病例。
研究设计与样本
- 研究纳入80例DBAS患者,携带不同核糖体蛋白基因致病变异:DBA1(RPS19,n=30)、DBA4(RPS17,n=6)、DBA5(RPL35A,n=8)、DBA6(RPL5,n=15)、DBA7(RPL11,n=13)、DBA10(RPS26,n=8)。
- 对6例分子未明确病例应用DBAS表观签名分析,并对其中2例后续行基因组测序。
主要发现
- 识别出DBAS独特且高度准确的表观签名生物标志物,可清晰区分范可尼贫血和广谱其他表观签名阳性疾病。
- 开发出针对临床相似的DBA6和DBA7亚型的特异性DNA甲基化分类器。
- 6例分子未明确病例中3例呈现DBAS模式,后续基因组测序在2例中鉴定出致病变异(RPL5:c.325-380A>G:p.?;RPL26:c.-6+3_-6+25del:p.?),验证了检测的稳健性。
- 两例回复突变病例(RPS19:P47L和RPS17全基因缺失)的甲基化谱呈现DBAS表观签名,提示其为与潜在遗传突变相关的稳定表观遗传标记,可能在发育早期建立。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diamond-Blackfan Anemia Syndrome (DBAS) is a rare inherited bone marrow failure syndrome (IBMFS) characterized by impaired erythropoiesis and significant genetic heterogeneity. Diagnosis can be challenging due to clinical variability and the lack of sensitive and specific biomarkers. We investigated the evidence for a DNA methylation (DNAm) episignature in a cohort of 80 DBAS patients with causative variants in various ribosomal protein genes: DBA1 (RPS19, n = 30), DBA4 (RPS17, n = 6), DBA5 (RPL35A, n = 8), DBA6 (RPL5, n = 15), DBA7 (RPL11, n = 13), DBA10 (RPS26, n = 8). We identified a distinct and highly accurate episignature biomarker for DBAS, clearly differentiating it from both Fanconi anemia and a broad spectrum of other episignature-positive disorders. Furthermore, we developed a specific DNAm classifier for the clinically similar DBA6 and DBA7 subtypes. Applying the DBAS episignature analysis to six molecularly uncharacterized cases, three exhibited the DBAS pattern. Subsequent genome sequencing identified causative genetic variants in two (RPL5: c.325-380A>G:p.?; RPL26: c.-6 + 3_-6 + 25del:p.?), validating the test robustness. Methylation profiles from two revertant cases (RPS19:P47L and RPS17 full gene deletion) exhibited the DBAS episignature, suggesting it to be a stable epigenetic mark associated with the underlying genetic mutation, likely established early in development. In conclusion, we propose DNAm profiling as a robust diagnostic tool for DBAS, providing a biomarker applicable to all patients with clinical suspicion of the disease and critically aiding in the resolution of variants of uncertain significance and molecularly uncharacterized cases.
引用
- Quarello P, Karimi K, Trajkova S, et al. DNA Methylation Episignature as a Novel Diagnostic Tool for Diamond-Blackfan Anemia Syndrome. Am J Hematol. 2025. PMID: 41247002. doi:10.1002/ajh.70141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。